Introduction Performance in cross-country skiing is influenced by the skier’s ability to continuously produce propelling forces and force magnitude in relation to the net external forces. A surrogate indicator of the “power supply” in cross-country skiing would be a physiological variable that reflects an important performance-related capability, whereas the body mass itself is an indicator of the “power demand” experienced by the skier. To adequately evaluate an elite skier’s performance capability, it is essential to establish the optimal ratio between the physiological variable and body mass. The overall aim of this doctoral thesis was to investigate the importance of body-mass exponent optimization for the evaluation of performance capability in cross-country skiing. Methods In total, 83 elite cross-country skiers (56 men and 27 women) volunteered to participate in the four studies. The physiological variables of maximal oxygen uptake (V̇O2max) and oxygen uptake corresponding to a blood-lactate concentration of 4 mmol∙l-1 (V̇O2obla) were determined while treadmill roller skiing using the diagonal-stride technique; mean oxygen uptake (V̇O2dp) and upper-body power output (Ẇ) were determined during double-poling tests using a ski-ergometer. Competitive performance data for elite male skiers were collected from two 15-km classical-technique skiing competitions and a 1.25-km sprint prologue; additionally, a 2-km double-poling roller-skiing time trial using the double-poling technique was used as an indicator of upper-body performance capability among elite male and female junior skiers. Power-function modelling was used to explain the race and time-trial speeds based on the physiological variables and body mass. Results The optimal V̇O2max-to-mass ratios to explain 15-km race speed were V̇O2max divided by body mass raised to the 0.48 and 0.53 power, and these models explained 68% and 69% of the variance in mean skiing speed, respectively; moreover, the 95% confidence intervals (CI) for the body-mass exponents did not include either 0 or 1. For the modelling of race speed in the sprint prologue, body mass failed to contribute to the models based on V̇O2max, V̇O2obla, and V̇O2dp. The upper-body power output-to-body mass ratio that optimally explained time-trial speed was Ẇ ∙ m-0.57 and the model explained 63% of the variance in speed. Conclusions The results in this thesis suggest that V̇O2max divided by the square root of body mass should be used as an indicator of performance in 15-km classical-technique races among elite male skiers rather than the absolute or simple ratio-standard scaled expression. To optimally explain an elite male skier’s performance capability in sprint prologues, power-function models based on oxygen-uptake variables expressed absolutely are recommended. Moreover, to evaluate elite junior skiers’ performance capabilities in 2-km double-poling roller-skiing time trials, it is recommended that Ẇ divided by the square root of body mass should be used rather than absolute or simple ratio-standard scaled expression of power output. / <p>Incorrect ISBN in printed thesis: 973-91-7601-270-3</p>

O cachorro-do-mato (Cerdocyon thous) é um canídeo neotropical que necessita ser contido por meios farmacológicos para a realização de certos procedimentos médicos e de manejo, em função de características comportamentais de defesa e grande susceptibilidade ao estresse. A combinação de seis protocolos (tiletamina-zolazepam-xilazina-atropina e azaperone; dextrocetamina-diazepam-xilazina-atropina e azaperone; cetamina racêmica-diazepam-xilazina-atropina e azaperone; tiletamina-zolazepam-detomidina-atropina e azaperone; dextrocetamina-diazepam-detomidina-atropina e azaperone; cetamina racêmica-diazepam-detomidina-atropina e azaperone) foram administradas, por via intramuscular, a dez cachorros-do-mato (nove machos e uma fêmea) com pesos médio 5,85 ± 0,83 kg, para possibilitar a realização de procedimentos de que incluíam marcação, exame físico, colheita de amostras de sangue, colheita de medula óssea e outros procedimentos pouco invasivos de moderada duração em Cerdocyon thous de cativeiro. Após a verificação dos pesos de cada cachorro-do-mato, a dose individual de cada uma das drogas foi calculada por meio de extrapolação alométrica interespecífica. O método proposto mostrou-se plenamente adequado à contenção farmacológica de exemplares de Cerdocyon thous que necessitem ser submetidos a procedimentos medianamente dolorosos ou incômodos, como exame físico e colheita de sangue e medula óssea. Não é indicado, porém, para procedimentos cirúrgicos. / The Crab-eating Fox (Cerdocyon thous) is a neotropical carnivorous that requires chemical restraint for handling due to its susceptibility to stress and characteristics of defensive behavior. Ten Crab-eating Fox (9 males and 1 female) weighing 5.85 ± 0.83 kg were given the combination of six protocols (tiletamine-zolazepam-xylazine-atropine and azaperone; dextroketamine-diazepam-xylazine-atropine and azaperone; racemic ketamine-diazepam-xylazine-atropine and azaperone; tiletamine-zolazepam-detomidine-atropine and azaperone; dextroketamina-diazepam-detomidine-atropine and azaperone; racemic ketamine-diazepam-detomidine-atropine and azaperone) by i.m. injection during field procedures that included identification, physical examination, blood sampling, bone marrow harvesting and other mildly invasive procedures of moderate duration in Cerdocyon thous of captivity. After checking the weights of each Crab-eating Fox, the individual dose of each drug was calculated by means of interspecific allometric extrapolation. The proposed method was safe for both the animal and the human personnel and it is recommended for routine management and stressful but not painful medical procedures like physical examination, measuring, sexing, and bone marrow and blood collection in Cerdocyon thous. / Tese (Doutorado)

Introduction Performance in cross-country skiing is influenced by the skier’s ability to continuously produce propelling forces and force magnitude in relation to the net external forces. A surrogate indicator of the “power supply” in cross-country skiing would be a physiological variable that reflects an important performance-related capability, whereas the body mass itself is an indicator of the “power demand” experienced by the skier. To adequately evaluate an elite skier’s performance capability, it is essential to establish the optimal ratio between the physiological variable and body mass. The overall aim of this doctoral thesis was to investigate the importance of body-mass exponent optimization for the evaluation of performance capability in cross-country skiing. Methods In total, 83 elite cross-country skiers (56 men and 27 women) volunteered to participate in the four studies. The physiological variables of maximal oxygen uptake (V̇O2max) and oxygen uptake corresponding to a blood-lactate concentration of 4 mmol∙l-1 (V̇O2obla) were determined while treadmill roller skiing using the diagonal-stride technique; mean oxygen uptake (V̇O2dp) and upper-body power output (Ẇ) were determined during double-poling tests using a ski-ergometer. Competitive performance data for elite male skiers were collected from two 15-km classical-technique skiing competitions and a 1.25-km sprint prologue; additionally, a 2-km double-poling roller-skiing time trial using the double-poling technique was used as an indicator of upper-body performance capability among elite male and female junior skiers. Power-function modelling was used to explain the race and time-trial speeds based on the physiological variables and body mass. Results The optimal V̇O2max-to-mass ratios to explain 15-km race speed were V̇O2max divided by body mass raised to the 0.48 and 0.53 power, and these models explained 68% and 69% of the variance in mean skiing speed, respectively; moreover, the 95% confidence intervals (CI) for the body-mass exponents did not include either 0 or 1. For the modelling of race speed in the sprint prologue, body mass failed to contribute to the models based on V̇O2max, V̇O2obla, and V̇O2dp. The upper-body power output-to-body mass ratio that optimally explained time-trial speed was Ẇ ∙ m-0.57 and the model explained 63% of the variance in speed. Conclusions The results in this thesis suggest that V̇O2max divided by the square root of body mass should be used as an indicator of performance in 15-km classical-technique races among elite male skiers rather than the absolute or simple ratio-standard scaled expression. To optimally explain an elite male skier’s performance capability in sprint prologues, power-function models based on oxygen-uptake variables expressed absolutely are recommended. Moreover, to evaluate elite junior skiers’ performance capabilities in 2-km double-poling roller-skiing time trials, it is recommended that Ẇ divided by the square root of body mass should be used rather than absolute or simple ratio-standard scaled expression of power output. / <p>Incorrect ISBN in printed thesis: 973-91-7601-270-3</p>

Un nouveau règlement (CE) n° 1901/2006 établi par le Parlement européen et le Conseil de l’UE, relatif aux médicaments à usage pédiatrique, vise à améliorer la santé et la qualité de vie des enfants en Europe, en garantissant que les nouveaux médicaments pédiatriques et les médicaments déjà commercialisés seront pleinement adaptés à leurs besoins spécifiques. Ce règlement prévoit de nouvelles obligations pour l'industrie pharmaceutique, assorties de récompenses et d'incitations. Dans ce contexte, un plan d’investigation pédiatrique a été proposé pour l’ivabradine dans plusieurs sous-groupes de la population pédiatrique dans le traitement de l’insuffisance cardiaque chronique. L’ivabradine est une molécule déjà commercialisée chez l’adulte dans la prise en charge de l’angor, et de l’insuffisance cardiaque. Un premier travail a été d’aider au design de cette étude pédiatrique : évaluer la formulation pédiatrique, aider au choix de la dose initiale à administrer chez l’enfant, choisir le protocole de prélèvements et conseiller la méthode de prélèvements. Pour évaluer la formulation pédiatrique, une étude a été conduite pour déterminer la biodisponibilité relative de la formulation pédiatrique par rapport aux comprimés utilisés chez l’adulte. Une biodisponibilité relative similaire a été retrouvée entre les deux formulations. Une approche physiologique (PBPK « Physiollogically based PharmacoKineticsmodel ») a été utilisé pour prédire la dose initiale à administrer et pour proposer un protocole de prélèvements PK. La méthode DBS (Dried blood spot) consistant à collecter à chaque temps de prélèvement une goutte de sang (au pli du coude ou au bout du doigt) a été recommandée. La première dose à administrer chez l’enfant peut être également être déterminée par des modèles de population développés chez l’adulte et adaptés à l’enfant grâce à l’allométrie et à l’ajout de fonctions de maturation. Cette approche a été comparée au PBPK dans le cas de l’ivabradine et des résultats similaires ont été obtenus. Un deuxième travail a été réalisé après que l’étude clinique ait été conduite dans la population pédiatrique. L’étude a été menée chez 116 enfants (74 enfants recevant l’ivabradine, 42 recevant le placebo) âgés de 6 mois à 18 ans et les données ont été analysées. Tout d’abord, une relation a été établie entre les concentrations d’ivabradine plasmatiques et les concentrations d’ivabradine mesurées dans le sang total. Puis, afin de décrire les concentrations d’ivabradine et de son métabolite, un modèle de population prenant en compte l’effet de l’âge et du poids a été développé. En comparant les expositions plasmatiques, une dose par kilogramme plus élevée aurait été nécessaire chez les patients les plus jeunes pour atteindre un niveau d’exposition similaire aux patients plus âgés. Enfin, il a été monté que la relation PK/PD qui avait développé chez l’adulte était conservée dans la population pédiatrique. / New legislation governing the development and authorization of medicines for use in children was introduced in the European Union (EU) in January 2007. This Regulation aims to facilitate the development and accessibility of medicinal products for use in the paediatric population, to ensure that medicinal products used to treat the paediatric population are subject to ethical research of high quality and are appropriately authorised for use in the paediatric population, and to improve the information available on the use of medicinal products in the various paediatric populations. Several rewards and incentives for the development of paediatric medicines for children are available in the European Union (EU). In compliance with the paediatric European regulation, a study will be conducted in paediatric patients with CHF with the objective to determine the efficacious and safe dose of ivabradine, a compound already marketed in adults, and to assess its efficacy and safety in children over 1 year old. A first work was to help design a paediatric study for ivabradine focusing on: the paediatric formulation evaluation, the doses to be administered, the sampling design and the sampling technique. A study was conducted in order to assess the relative bioavailability (Frel) of the paediatric formulation and a similar Frel was observed between the paediatric formulation and the adult marketed tablet. PBPK modelling was used to predict initial doses to be administered in the paediatric study and to select the most appropriate sample time collections. The dried blood spot (DBS) technique was recommended in the clinical trial in children. A secondary objective was to perform a comparison of the prediction of ivabradine pharmacokinetics (PK) in children using a physiologically-based pharmacokinetic (PBPK) approach and allometric scaling of a population pharmacokinetic (PPK) model. Simulations obtained by both the PBPK approach and allometric scaling of a PPK model were compared a posteriori to the paediatric study observations. Both PPK and PBPK approaches allowed an adequate prediction of the PK of ivabradine and its metabolite in children. The second work was done after the study conduction in the paediatric population. The study was performed in 116 children (74 received ivabradine, 42 received the placebo) aged from 6 months to less than 18 years old and data were analysed. The relationship between blood and plasma concentrations was described using linear mixed effect models. In order to describe ivabradine and its metabolite blood concentrations in children, a joint population PK model was developed taking into account weight & age effects on PK parameters. Plasma exposure comparison indicated that higher dose/kg were necessary to achieve a similar exposure between younger and older children. The PK/PD relationship in adult patients is conserved in children.

Introduction: No Fixed-Dose Combination (FDC) formulations currently exist for pediatric tuberculosis (TB) treatment. Earlier work implemented, in the software NONMEM, a rational method for optimizing design and individualization of pediatric anti-TB FDC formulations based on patient body weight, but issues with parameter estimation, dosage strata heterogeneity and representative pharmacokinetics remained. Aim: To further develop the rational model-based methodology aiding the selection of appropriate FDC formulation designs and dosage regimens, in pediatric TB treatment. Materials and Methods: Optimization of the method with respect to the estimation of body weight breakpoints was sought. Heterogeneity of dosage groups with respect to treatment efficiency was sought to be improved. Recently published pediatric pharmacokinetic parameters were implemented and the model translated to MATLAB, where also the performance was evaluated by stochastic estimation and graphical visualization. Results: A logistic function was found better suited as an approximation of breakpoints. None of the estimation methods implemented in NONMEM were more suitable than the originally used FO method. Homogenization of dosage group treatment efficiency could not be solved. MATLAB translation was successful but required stochastic estimations and highlighted high densities of local minima. Representative pharmacokinetics were successfully implemented. Conclusions: NONMEM was found suboptimal for the task due to problems with discontinuities and heterogeneity, but a stepwise method with representative pharmacokinetics were successfully implemented. MATLAB showed more promise in the search for a method also addressing the heterogeneity issue.

Les perturbations auxquelles font face les communautés écologiques, du fait des activités humaines, sont à l'origine de changements profonds dans ces communautés. Nombreuses caractéristiques des espèces sont altérées, de leur physiologie à leur occurrence même. Ces changements se répercutent sur la composition, la diversité et la structure des communautés, puisque les espèces n'interagissent pas tout le temps de la même manière en fonction des conditions. Prévoir le devenir de ces communautés émergentes, et des fonctions qu'elles soutiennent est un défi central de l'écologie et de nos sociétés. Différents cadres conceptuels ont été utilisés pour relever ce défi, basés sur différents mécanismes écologiques, et ont divergé en plusieurs domaines. D'un côté, l'analyse des chaînes trophiques utilise la consommation pour expliquer les effets de la diversité verticale (le nombre de niveaux trophiques) sur le fonctionnement, et de l'autre côté, les analyses biodiversité-fonctionnement lient compétition et effets de la diversité horizontale (la diversité au sein des niveaux trophiques isolés). Chacun de ces domaines a produit des résultats clés pour comprendre les conséquences fonctionnelles des changements de composition et diversité des communautés écologiques. Cependant, ils sont chacun basés sur différentes simplifications fortes des communautés. L'hypothèse qui sous-tend cette thèse est que la réconciliation en un même cadre de travail des résultats fondamentaux de ces champs conceptuels divergents, ainsi que des effets des changements de structure de la biodiversité, est une étape clé pour pouvoir améliorer notre compréhension du fonctionnement de communautés écologiques en changement. L'essor récent des méthodes d'analyse des réseaux trophiques, et des modèles permettant de simuler le fonctionnement de ces réseaux trophiques offre un cadre idéal pour cette réconciliation. En effet, les réseaux trophiques cartographient les échanges de matière entre toutes les espèces d'une communauté, permettant la mise en place d'interactions variées. Ils reflètent mieux la réalité complexe des communautés que les chaînes trophiques ou leurs niveaux trophiques isolés en intégrant notamment compétition et consommation. Un modèle ressource-consommateur bioénergétique classique, développé par Yodzis et Innes (1992), permet d'en simuler le fonctionnement, en intégrant des mécanismes et taux testés empiriquement. Au-delà d'utiliser ces outils, cette thèse se concentre aussi sur leur évaluation. Après un premier chapitre d'introduction, le second chapitre propose une plateforme ouverte, commune, solidement testée et efficace pour l'utilisation du modèle bioénergétique, permettant ainsi une synthèse plus rapide et aisée des résultats. Le troisième chapitre est une revue du corpus méthodologique d'analyse des réseaux trophiques, proposant une gamme de méthodes robustes et informatives, et soulignant leur domaine d'application et leurs limites. Enfin le quatrième chapitre met ce cadre méthodologique à l'épreuve. Dans ce chapitre, nous montrons l'existence d'une relation entre la complexité de la structure du réseau trophique des communautés et leur régime de fonctionnement, se traduisant par la réalisation de différentes prédictions issues de l'analyse des chaînes trophiques ou des analyses diversité-fonctionnement. Cette mise en évidence des conditions structurelles pour la réalisation de différentes prédictions nous permet de mieux comprendre quels mécanismes écologiques prédominent selon différentes conditions, dirigeant l'effet de la diversité sur le fonctionnement. / Human-driven disturbances are causing profound changes in ecological communities, as many characteristics of species are altered, from their physiology to their very occurrence. These changes affect the composition, diversity and structure of communities, since species do not always interact in the same way under different conditions. Predicting the fate of these emerging communities, and the functions they support, is a central challenge for ecology and our societies. Diverging conceptual frameworks have been used to address this challenge, based on different ecological mechanisms. On the one hand, food chain analysis uses consumption to explain the effects of vertical diversity (the number of trophic levels) on functioning, and on the other hand, biodiversity-functioning analyses link competition and the effects of horizontal diversity (diversity within isolated trophic levels). Each of these domains has produced key results for understanding the functional consequences of changes in the composition and diversity of ecological communities. However, they are each based on different strong simplifications of communities. The hypothesis underlying this thesis is that reconciling the fundamental results of these divergent conceptual fields, as well as the effects of changes in the structure of biodiversity, into a single framework is a key step towards improving our understanding of the functioning of changing ecological communities. The recent development of food web analysis and of models to simulate food webs functioning provides an ideal framework for this reconciliation. Food webs map the exchange of matter between all species in a community, allowing for a variety of interactions to take place. They better reflect the complex reality of communities than food chains or their isolated trophic levels, notably by integrating competition and consumption. A classical consumer-resource bioenergetic model developed by Yodzis and Innes (1992) specifically makes it possible to realistically simulate their functioning, using empirically tested mechanisms and rates. Beyond using these tools, this thesis focuses on their evaluation and implementation. After a first, introductory chapter, the second chapter proposes an open, common, well-tested and efficient platform for the use of the bioenergetic model, allowing a faster and easier synthesis of the results. The third chapter is a review of the methodological corpus for ecological networks analysis, outlining a range of robust and informative methods, and highlighting their scope and limitations. Finally, the fourth chapter puts this methodological framework to the test. In this chapter, we show the existence of a relationship between the complexity of communities' food-web structure and functioning regime, resulting in the realization of different predictions from food chain analysis or diversity-functioning analyses. This demonstration of the structural conditions for the realization of different predictions allows us to better understand which ecological mechanisms predominate under different conditions, directing the effect of diversity on functioning.